Is Automated Insulin Delivery System Therapy Safe and Effectıve in Children Under 7 Years Old?

Is Automated Insulin Delivery System Therapy Safe and Effectıve in Children Under 7 Years Old?

This study aims to evaluate the off-label use of the MiniMed™ 780G system in children under seven years old. Children under seven years with type 1 diabetes (T1D) using MiniMed™ 780G were retrospectively compared with children of similar age and gender using MiniMed™ 640G and multiple-dose insulin (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical research in pediatric endocrinology 2024-11
Hauptverfasser: Uslu, Nihal Gul, Ozalp Kizilay, Deniz, Demir, Gunay, Atik Altinok, Yasemin, Darcan, Sukran, Ozen, Samim, Göksen, Damla
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Journal of clinical research in pediatric endocrinology
container_volume
creator Uslu, Nihal Gul
Ozalp Kizilay, Deniz
Demir, Gunay
Atik Altinok, Yasemin
Darcan, Sukran
Ozen, Samim
Göksen, Damla
description This study aims to evaluate the off-label use of the MiniMed™ 780G system in children under seven years old. Children under seven years with type 1 diabetes (T1D) using MiniMed™ 780G were retrospectively compared with children of similar age and gender using MiniMed™ 640G and multiple-dose insulin (MDI) therapy with continuous glucose monitoring systems (CGMs). CGM metrics, total daily insulin dose (TDI), and HbA1c levels were evaluated retrospectively at baseline and at the 3rd, 6th, and 12th months. At the initiation of MiniMed™ 780G therapy, the mean age was 5,25±1,22 years (range: 2,8–6,8 years). Glucose management indicator (GMI) and HbA1c remained lower in the MiniMed™ 780G group at the 3rd, 6th, and 12th months compared to baseline (p=0,009 and p
doi_str_mv 10.4274/jcrpe.galenos.2024.2024-11-2
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3130828577</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3130828577</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1632-5d865ede623c2d0fe0d1b458c913abcea30a7b8d5a461b4e4b46bc157c3127953</originalsourceid><addsrcrecordid>eNo9kMtKxDAUhoMoKqOvIFm4cNMx16YFQWQcdWDAhbpwFdLk1Kmk7Zi0A_NYvoMPZueiZ3EunP8_Bz6ELikZC6bE9acNSxh_GA9NG8eMMLFNCaUJO0CnlJMskYrLw_-eqRN0HuMnGUIIRaQ8Ric8l6nIU3WK9Cziu75ra9OBw7Mm9r5q8D34agVhjV_WsYMavy4gmOUwmhKwaRyeliXY7ud7BXiQTxaVdwEa_NY4CFjhdzAh4mfvbs_QUWl8hPN9HaG3h-nr5CmZPz_OJnfzxNKUs0S6LJXgIGXcMkdKII4WQmY2p9wUFgwnRhWZk0akwwJEIdLCUqksp0zlko_Q1e7uMrRfPcRO11W04L1poO2j5hscLJNKDdKbndSGNsYApV6GqjZhrSnRG8p6S1nvKesN4F2iVLPBfrH_1Bc1uH_zH1P-C_a-fQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3130828577</pqid></control><display><type>article</type><title>Is Automated Insulin Delivery System Therapy Safe and Effectıve in Children Under 7 Years Old?</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Uslu, Nihal Gul ; Ozalp Kizilay, Deniz ; Demir, Gunay ; Atik Altinok, Yasemin ; Darcan, Sukran ; Ozen, Samim ; Göksen, Damla</creator><creatorcontrib>Uslu, Nihal Gul ; Ozalp Kizilay, Deniz ; Demir, Gunay ; Atik Altinok, Yasemin ; Darcan, Sukran ; Ozen, Samim ; Göksen, Damla</creatorcontrib><description>This study aims to evaluate the off-label use of the MiniMed™ 780G system in children under seven years old. Children under seven years with type 1 diabetes (T1D) using MiniMed™ 780G were retrospectively compared with children of similar age and gender using MiniMed™ 640G and multiple-dose insulin (MDI) therapy with continuous glucose monitoring systems (CGMs). CGM metrics, total daily insulin dose (TDI), and HbA1c levels were evaluated retrospectively at baseline and at the 3rd, 6th, and 12th months. At the initiation of MiniMed™ 780G therapy, the mean age was 5,25±1,22 years (range: 2,8–6,8 years). Glucose management indicator (GMI) and HbA1c remained lower in the MiniMed™ 780G group at the 3rd, 6th, and 12th months compared to baseline (p=0,009 and p&lt;0,001, respectively), Time Above Range (TAR) was significantly lower at the 3rd, 6th, and 12th months (p=0,018, 0,017, 0,04, respectively), and Time in Range (TIR) was higher at the 3rd and 12th months (p=0,026 and 0,019, respectively) compared with the other groups. No instances of ketoacidosis or severe hypoglycemic events were observed in any of the children during the follow-up period. The absence of significantly higher levels of hypoglycemia compared to other groups at any time point, along with a significant decrease in TAR across all time points, a significant increase in TIR at the 3rd and 12th months, and a significant decrease in HbA1c and CV, indicates that the MiniMed™ 780G system is both safe and effective for children under seven years old.</description><identifier>ISSN: 1308-5727</identifier><identifier>ISSN: 1308-5735</identifier><identifier>EISSN: 1308-5735</identifier><identifier>DOI: 10.4274/jcrpe.galenos.2024.2024-11-2</identifier><identifier>PMID: 39564967</identifier><language>eng</language><publisher>Turkey</publisher><ispartof>Journal of clinical research in pediatric endocrinology, 2024-11</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39564967$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Uslu, Nihal Gul</creatorcontrib><creatorcontrib>Ozalp Kizilay, Deniz</creatorcontrib><creatorcontrib>Demir, Gunay</creatorcontrib><creatorcontrib>Atik Altinok, Yasemin</creatorcontrib><creatorcontrib>Darcan, Sukran</creatorcontrib><creatorcontrib>Ozen, Samim</creatorcontrib><creatorcontrib>Göksen, Damla</creatorcontrib><title>Is Automated Insulin Delivery System Therapy Safe and Effectıve in Children Under 7 Years Old?</title><title>Journal of clinical research in pediatric endocrinology</title><addtitle>J Clin Res Pediatr Endocrinol</addtitle><description>This study aims to evaluate the off-label use of the MiniMed™ 780G system in children under seven years old. Children under seven years with type 1 diabetes (T1D) using MiniMed™ 780G were retrospectively compared with children of similar age and gender using MiniMed™ 640G and multiple-dose insulin (MDI) therapy with continuous glucose monitoring systems (CGMs). CGM metrics, total daily insulin dose (TDI), and HbA1c levels were evaluated retrospectively at baseline and at the 3rd, 6th, and 12th months. At the initiation of MiniMed™ 780G therapy, the mean age was 5,25±1,22 years (range: 2,8–6,8 years). Glucose management indicator (GMI) and HbA1c remained lower in the MiniMed™ 780G group at the 3rd, 6th, and 12th months compared to baseline (p=0,009 and p&lt;0,001, respectively), Time Above Range (TAR) was significantly lower at the 3rd, 6th, and 12th months (p=0,018, 0,017, 0,04, respectively), and Time in Range (TIR) was higher at the 3rd and 12th months (p=0,026 and 0,019, respectively) compared with the other groups. No instances of ketoacidosis or severe hypoglycemic events were observed in any of the children during the follow-up period. The absence of significantly higher levels of hypoglycemia compared to other groups at any time point, along with a significant decrease in TAR across all time points, a significant increase in TIR at the 3rd and 12th months, and a significant decrease in HbA1c and CV, indicates that the MiniMed™ 780G system is both safe and effective for children under seven years old.</description><issn>1308-5727</issn><issn>1308-5735</issn><issn>1308-5735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kMtKxDAUhoMoKqOvIFm4cNMx16YFQWQcdWDAhbpwFdLk1Kmk7Zi0A_NYvoMPZueiZ3EunP8_Bz6ELikZC6bE9acNSxh_GA9NG8eMMLFNCaUJO0CnlJMskYrLw_-eqRN0HuMnGUIIRaQ8Ric8l6nIU3WK9Cziu75ra9OBw7Mm9r5q8D34agVhjV_WsYMavy4gmOUwmhKwaRyeliXY7ud7BXiQTxaVdwEa_NY4CFjhdzAh4mfvbs_QUWl8hPN9HaG3h-nr5CmZPz_OJnfzxNKUs0S6LJXgIGXcMkdKII4WQmY2p9wUFgwnRhWZk0akwwJEIdLCUqksp0zlko_Q1e7uMrRfPcRO11W04L1poO2j5hscLJNKDdKbndSGNsYApV6GqjZhrSnRG8p6S1nvKesN4F2iVLPBfrH_1Bc1uH_zH1P-C_a-fQA</recordid><startdate>20241120</startdate><enddate>20241120</enddate><creator>Uslu, Nihal Gul</creator><creator>Ozalp Kizilay, Deniz</creator><creator>Demir, Gunay</creator><creator>Atik Altinok, Yasemin</creator><creator>Darcan, Sukran</creator><creator>Ozen, Samim</creator><creator>Göksen, Damla</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20241120</creationdate><title>Is Automated Insulin Delivery System Therapy Safe and Effectıve in Children Under 7 Years Old?</title><author>Uslu, Nihal Gul ; Ozalp Kizilay, Deniz ; Demir, Gunay ; Atik Altinok, Yasemin ; Darcan, Sukran ; Ozen, Samim ; Göksen, Damla</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1632-5d865ede623c2d0fe0d1b458c913abcea30a7b8d5a461b4e4b46bc157c3127953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Uslu, Nihal Gul</creatorcontrib><creatorcontrib>Ozalp Kizilay, Deniz</creatorcontrib><creatorcontrib>Demir, Gunay</creatorcontrib><creatorcontrib>Atik Altinok, Yasemin</creatorcontrib><creatorcontrib>Darcan, Sukran</creatorcontrib><creatorcontrib>Ozen, Samim</creatorcontrib><creatorcontrib>Göksen, Damla</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical research in pediatric endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Uslu, Nihal Gul</au><au>Ozalp Kizilay, Deniz</au><au>Demir, Gunay</au><au>Atik Altinok, Yasemin</au><au>Darcan, Sukran</au><au>Ozen, Samim</au><au>Göksen, Damla</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is Automated Insulin Delivery System Therapy Safe and Effectıve in Children Under 7 Years Old?</atitle><jtitle>Journal of clinical research in pediatric endocrinology</jtitle><addtitle>J Clin Res Pediatr Endocrinol</addtitle><date>2024-11-20</date><risdate>2024</risdate><issn>1308-5727</issn><issn>1308-5735</issn><eissn>1308-5735</eissn><abstract>This study aims to evaluate the off-label use of the MiniMed™ 780G system in children under seven years old. Children under seven years with type 1 diabetes (T1D) using MiniMed™ 780G were retrospectively compared with children of similar age and gender using MiniMed™ 640G and multiple-dose insulin (MDI) therapy with continuous glucose monitoring systems (CGMs). CGM metrics, total daily insulin dose (TDI), and HbA1c levels were evaluated retrospectively at baseline and at the 3rd, 6th, and 12th months. At the initiation of MiniMed™ 780G therapy, the mean age was 5,25±1,22 years (range: 2,8–6,8 years). Glucose management indicator (GMI) and HbA1c remained lower in the MiniMed™ 780G group at the 3rd, 6th, and 12th months compared to baseline (p=0,009 and p&lt;0,001, respectively), Time Above Range (TAR) was significantly lower at the 3rd, 6th, and 12th months (p=0,018, 0,017, 0,04, respectively), and Time in Range (TIR) was higher at the 3rd and 12th months (p=0,026 and 0,019, respectively) compared with the other groups. No instances of ketoacidosis or severe hypoglycemic events were observed in any of the children during the follow-up period. The absence of significantly higher levels of hypoglycemia compared to other groups at any time point, along with a significant decrease in TAR across all time points, a significant increase in TIR at the 3rd and 12th months, and a significant decrease in HbA1c and CV, indicates that the MiniMed™ 780G system is both safe and effective for children under seven years old.</abstract><cop>Turkey</cop><pmid>39564967</pmid><doi>10.4274/jcrpe.galenos.2024.2024-11-2</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1308-5727
ispartof Journal of clinical research in pediatric endocrinology, 2024-11
issn 1308-5727
1308-5735
1308-5735
language eng
recordid cdi_proquest_miscellaneous_3130828577
source DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
title Is Automated Insulin Delivery System Therapy Safe and Effectıve in Children Under 7 Years Old?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T06%3A08%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20Automated%20Insulin%20Delivery%20System%20Therapy%20Safe%20and%20Effect%C4%B1ve%20in%20Children%20Under%207%20Years%20Old?&rft.jtitle=Journal%20of%20clinical%20research%20in%20pediatric%20endocrinology&rft.au=Uslu,%20Nihal%20Gul&rft.date=2024-11-20&rft.issn=1308-5727&rft.eissn=1308-5735&rft_id=info:doi/10.4274/jcrpe.galenos.2024.2024-11-2&rft_dat=%3Cproquest_cross%3E3130828577%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3130828577&rft_id=info:pmid/39564967&rfr_iscdi=true